Alnylam Pharmaceuticals was granted a China patent on a crucial short interfering RNAs (siRNAs) patent, the Tuschl II series. This patent includes 44 claims covering compositions, methods, uses, and systems for siRNAs, the molecules that mediate RNAi. Previously, Alnylam was awarded a patent for the Tuschl II claims in the US, Europe, Japan and Australia. Alnylam licensed the patents from Max Planck Innovation GmbH. More details...

Stock Symbol: (NSDQ: ALNY)